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Abstract 1 
Background: Immune-modulating drugs have recently been introduced to the second 2 
line setting of advanced bladder cancer. Pembrolizumab increases overall survival and 3 
is associated with less toxicity compared to chemotherapy in this setting based on the 4 
Keynote 045 study. The high cost of immunotherapy necessitates an assessment of its 5 
value by considering both efficacy and cost.  6 
Objective: To estimate the cost-effectiveness of pembrolizumab for the second-line 7 
treatment of advanced bladder cancer from the perspective of payers in multiple 8 
countries. 9 
Design, Setting, and Participants: We developed a Markov model to compare the 10 
costs and effectiveness of pembrolizumab with those of chemotherapy in the second-11 
line treatment of advanced bladder cancer based on the Keynote 045 study. Drug costs 12 
were acquired for the following countries: U.S., U.K., Canada and Australia. All costs 13 
were converted from local currency to U.S. dollars at the exchange rates in September 14 
2017.  15 
Outcome Measurements and Statistical Analysis: Health outcomes were measured 16 
in quality-adjusted life-years (QALYs).  17 
Results and Limitation: Pembrolizumab generated a gain of 0.36-0.37 QALYs 18 
compared to chemotherapy. Our analysis established the following incremental cost-19 
effectiveness ratios (ICERs) for pembrolizumab versus chemotherapy in second-line 20 
advanced bladder cancer treatment - U.S. $122,557/QALY, U.K. $91,995/QALY, 21 
Canada $90,099/QALY, and Australia $99,966/QALY. The willingness-to-pay 22 
(WTP) thresholds per QALY are considered to be around 100,000-150,000 US dollars 23 
for the U.S., 20,000-50,000 pounds for the U.K. [US$25,000-65,000], 20,000-100,000 24 
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CAD for Canada [US$16,000-80,000] and 40,000-75,000 AUD for Australia 25 
[US$32,000-60,000]. 26 
Conclusions: Cost-effectiveness and WTP thresholds vary between countries. 27 
Compared to the other countries examined, U.S. drug prices were found to be highest, 28 
leading to the highest ICER. With standard willingness-to-pay thresholds, 29 
pembrolizumab may be considered cost-effective in the U.S., but not in the other 30 
countries examined. 31 
 32 
Patient summary: This article assessed the cost-effectiveness of pembrolizumab for 33 
treatment of patients with metastatic bladder cancer who have previously failed one 34 
treatment regimen. It would cost $122,557 in the U.S., $91,995 in the U.K., $90,099 35 
in Canada and $99,966 in Australia to gain one quality-adjusted life-year with 36 
pembrolizumab versus chemotherapy in these patients, which may be considered cost-37 
effective only in the U.S. because of differences in willingness-to-pay thresholds. 38 
 39 
 40 
  41 
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Introduction 42 
Metastatic bladder cancer is a lethal disease, with only 5% of patients surviving 5 43 
years1. Platinum-based chemotherapy is the standard of care for patients with 44 
advanced disease. Unfortunately, after disease progression; second-line chemotherapy 45 
yields a response rate of only around 10% with considerable toxicities2. Recently, 46 
immunotherapy has shown activity in advanced bladder cancer, with 5 checkpoint 47 
inhibitors gaining FDA approval for second-line therapy (pembrolizumab, nivolumab, 48 
atezolizumab, avelumab, durvalumab)3. Pembrolizumab is the only FDA approved 49 
checkpoint inhibitor that has so far shown an overall survival benefit in this 50 
indication, based on the Keynote 045 study4. This pivotal phase III study 51 
demonstrated a 2.9 month improved median overall survival with pembrolizumab 52 
compared to chemotherapy (10.3 vs. 7.4 months, hazard ratio 0.73). Responding 53 
patients on pembrolizumab tended to have longer responses, and the flattening of the 54 
survival curve for pembrolizumab hints towards durable survival in some patients. 55 
The toxicity profile was also improved, with patients typically suffering from asthenia 56 
and infrequently from immune-mediated side effects.  57 
 58 
The growing cost of cancer care in the era of immunotherapy is of great concern for 59 
public and private payers and for individual patients around the world. This concern 60 
triggered both the American5 and European6 oncology societies to develop value 61 
frameworks for cancer drugs. A standard, well validated method to examine a drug's 62 
value is by a cost-effectiveness analysis (CEA), which considers both cost and 63 
efficacy in its specific indication. As drug prices and willingness to pay thresholds 64 
vary around the world7, the CEA estimates the value in a specific setting and is not 65 
exchangeable between countries. The objective of this study was to estimate the cost-66 
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effectiveness of pembrolizumab for second-line treatment of advanced bladder cancer 67 
from the perspective of payers in multiple countries, specifically the U.S., U.K., 68 
Canada and Australia. 69 
  70 
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Methods 71 
Model Structure 72 
The Markov model involved an initial treatment decision with either pembrolizumab 73 
or chemotherapy (Fig. 1). Patients then transitioned through different health states: 74 
stable/responsive (progression free) disease, progressive disease, and death. Each 75 
model cycle represented 1 month over a 5-year time horizon. All patients started with 76 
stable, progression-free disease and either remained at that stage or transitioned to 77 
progressive disease or death. Once in the progressive stage, patients could remain in 78 
that stage or transition to death.  79 
 80 
The primary outputs of the model were cost and Quality Adjusted Life Years 81 
(QALYs), which were used to calculate the incremental cost effectiveness ratio 82 
(ICER). The Markov model was implemented in TreeAgePro 2016 software (TreeAge 83 
Software Inc., Williamstown, MA, USA), and statistical analyses were performed in 84 
Matlab 2016-B software (MathWorks Inc., Natick, MA, USA). 85 
 86 
Mortality estimates 87 
The probability for transition from a progression-free state to a post-progression state 88 
was derived from the Progression-Free Survival (PFS) curves in the Keynote 045 trial. 89 
The probability for transition from any state to the death state was derived from the 90 
overall survival (OS) curves in the Keynote 045 trial. For the pembrolizumab and 91 
chemotherapy arms we used Plot Digitizer software (version 2.1; http://plotdigitizer. 92 
sourceforge.net) to extract the data points from each PFS and OS plot from the 93 
Keynote 045 trial, and these data points were then used to fit parametric models. 94 
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Weibull distribution was used as it provided the best fit for all curves. (See 95 
supplemental material) 96 
 97 
Utility estimates 98 
To compute the total quality adjusted life years (QALYs) in the Markov models, 99 
survival time was adjusted by the health-related quality of life (HRQL). The health 100 
utility score was based on quality-of life data collected in the Keynote 045. In the 101 
trial, quality-of life8 was assessed with the European Organization for Research and 102 
Treatment of Cancer quality-of life questionnaire C30 (EORTC QLQ-C30) 103 
questionnaire. EORTC QLQ-C30 score was assessed at cycles 1–4, then every 2 104 
cycles for up to 1 year. In the model, based on the trial, we incorporated a baseline 105 
utility of 0.6 for all patients for weeks 1-14 and a utility of 0.61 for the 106 
pembrolizumab arm and 0.52 for the chemotherapy arm from week 15 until death. We 107 
used ±10% as the boundaries of the range in sensitivity analyses.  108 
 109 
Cost estimates 110 
Only direct medical costs were considered including drug, administration, and adverse 111 
event (AE) costs. The cost of pembrolizumab administration was calculated for 112 
intravenous treatment at a dose of 200mg every 3 weeks until disease progression for 113 
a maximum of 2 years. The cost of chemotherapy administration was calculated as the 114 
mean cost of docetaxel 75mg/m2 (including dexamethasone 8 mg PO bid for 3 days) 115 
and paclitaxel 175mg/m2, administration intravenously every 3 weeks until disease 116 
progression. The cost of vinflunine was not accounted for, as it is not FDA approved 117 
and is not used for this indication in the U.S.. To calculate doses, we used a mean 118 
body surface area (BSA) of 1.86 m2.9  119 
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 120 
We included in the model grade 3 to 4 AEs that had significantly different rates 121 
between the arms of the Keynote 045 trial4, which were anemia, neutropenia and 122 
febrile neutropenia. The treatment of AEs was estimated based on clinical experience, 123 
similar to a previous study10. We assumed that an episode of febrile neutropenia 124 
would be managed with a 5-day hospitalization. We assumed that grade 3/4 anemia 125 
would be managed with one outpatient visit and transfusion of two units of red blood 126 
cells (RBC). All costs and health outcomes were discounted by 3% annually for the 127 
U.S., U.K. and Australia11, and 1.5% for Canada12. We adjusted all cost estimates for 128 
each individual country, similar to a previous study11. We used prices that, to the best 129 
of our knowledge, account for non-confidential discounts and rebates. However we 130 
were unable to account for any country specific confidential discounts. Details of drug 131 
costs are available in Table 1 and in the supplemental material. 132 
 133 
Sensitivity analysis 134 
A series of sensitivity analyses was performed to evaluate the robustness of the model 135 
and to address the uncertainty in the estimation of variables. Utilities incorporated a 136 
±10% range as described above. Drug costs varied within ±20% of their baseline 137 
values to account for alternative public and private payers that may pay less or more 138 
respectively, as in a similar study13. In univariate sensitivity analyses, we varied the 139 
value of one parameter at a time over its defined range and examined the effect on the 140 
ICER. In probabilistic sensitivity analyses (PSA), we ran the model 10,000 times, 141 
each time randomly varying all parameters simultaneously according to the sampling 142 
distributions. 143 
 144 
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 145 
Structural sensitivity analysis 146 
We performed two structural sensitivity analyses, one incorporating the price of 147 
vinflunine to the U.K. model, and the other comparing pembrolizumab to best 148 
supportive care (assuming no survival benefit with taxanes). 149 
 150 
Net Benefit Calculation 151 
Net Health Benefit (NHB) expresses the ICER on a single scale in units of QALYs. It 152 
requires pre-specification of a fixed monetary value of a QALY, which can be 153 
considered to be the opportunity cost of losing one QALY from a health system14,15. 154 
This is equivalent to a back-calculated cost-effectiveness threshold. Using this, we 155 
calculated the country-specific value of pembrolizumab, subject to local pricing, using 156 
the value-metric of incremental NHB per person treated (expressed in QALYs where 157 
higher values represent higher value). 158 
 159 
Results 160 
Base Case Results 161 
Pembrolizumab generated a gain of 0.36 QALYs over chemotherapy for the U.S., 162 
U.K. and Australia, and 0.37 QALY for Canada (due to different discounting rates). 163 
In the U.S., U.K., Canada, and Australia, in comparison with the base case results, the 164 
ICER, meaning the additional cost of pembrolizumab versus chemotherapy was 165 
$122,557, $91,995, $90,099, and $99,966 per QALY gained, respectively. Table 2 166 
demonstrates these base case results. 167 
 168 
Sensitivity Analyses 169 
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The results of univariate sensitivity analyses are presented in the tornado diagram (in 170 
supplemental material). The parameters with the greatest influence on the ICER were 171 
those of the overall survival extrapolation. The effects of other parameters were 172 
negligible. The results of the probabilistic sensitivity analyses are shown in the cost-173 
effectiveness acceptability curves (Fig 2). These curves show the probability that 174 
pembrolizumab is cost-effective across increasing willingness-to-pay (WTP) 175 
thresholds. These results demonstrated 100% probability in all countries analyzed that 176 
pembrolizumab is cost-effective compared to chemotherapy at WTP thresholds of 177 
$150,000 per QALY.  178 
 179 
Country-Specific Value Estimates 180 
Expressed as NHB, the country specific estimates of the value of pembrolizumab 181 
versus chemotherapy are as follows: U.S. -1.46 to -0.74 QALYs; U.K. -1.42 to -1.42 182 
QALYs; Canada -1.24 to -0.91 QALYs; Australia -1.34 to -0.98 QALYs. This 183 
approach suggests that country-specific prices result in Australia obtaining best value 184 
for money and the U.K. likely the worst, taking into account the country-specific 185 
opportunity cost of investment in the new technology. 186 
 187 
Discussion 188 
We performed a cost-effectiveness analysis of pembrolizumab versus chemotherapy 189 
in 2nd line advanced bladder cancer from a global perspective, including 4 countries - 190 
U.S., U.K., Canada and Australia.  A single treatment with pembrolizumab costs 15-191 
50 times more per cycle compared with chemotherapy. The added cost for 192 
pembrolizumab over chemotherapy is lower in the U.K., Australia, and Canada 193 
(~$33,000-$36,000) than in the U.S. (~$44,000), resulting in lower ICERs in these 194 
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countries (~$90,000-$100,000 versus ~$120,000 per QALY gained). Prices vary 195 
around the world due to differences in regulations and negotiations with drug 196 
companies. U.S. prices are known to be higher than other countries as every FDA 197 
approved drug is reimbursed by Medicare without the ability to negotiate16. Although 198 
the intervention is more expensive in the U.S., due to a higher theoretical WTP 199 
threshold it is the only country in which the drug may potentially be considered to be 200 
cost-effective. 201 
It is important to note that the WTP threshold varies between different countries and 202 
is a matter of much debate, as its precise figure is elusive. In the U.S. the WTP 203 
threshold is considered to be $50,000-150,000 per QALY17, although many cancer 204 
drugs are in use despite an ICER above this threshold13. In the U.K. the WTP 205 
threshold is considered to be 20,000-30,000 pounds [25,000-38,000 US $] and 50,000 206 
pounds [~65,000 US $] if the drug meets the end-of-life criteria (life-prolonging by 207 
more than 3 months in a disease with a prognosis of less than 24 months)18. For 208 
Canada and Australia there is no explicit WTP threshold for recommendation-making 209 
by the pan-Canadian Oncology Drug Review (pCODR)/Canadian Agency in Drug 210 
and Technology in Health (CADTH) nor the Australian Pharmaceutical Benefits 211 
Advisory Committee (PBAC). We used for this paper a Canadian threshold of 20,000-212 
100,000 CAD [16,000-80,000 US $], as discussed by Laupacis et al19 and an 213 
Australian threshold of 40,000-75,000 AUD [32,000-60,000 US $], as conferred by 214 
George et al20. The World Health Organization21 recommends using a WTP threshold 215 
of two to three times the gross domestic product per capita per disability-adjusted life-216 
year (DALY) averted. These different thresholds and their impact on the decision 217 
whether pembrolizumab is cost-effective are presented in Table 2. In August 2017 the 218 
U.K. National Institute for Health and Care Excellence (NICE) announced that 219 
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pembrolizumab is not cost-effective for metastatic bladder cancer due to its high cost, 220 
despite meeting the end-of-life criteria22.  221 
Our analysis was limited by data availability and our assumptions. We assumed that 222 
survival benefits, utilities, and AE incidence and management were standard between 223 
countries. We used American data for mean BSA, which might differ slightly between 224 
countries. We did not include taxes on drug costs for any country, as tax rates and 225 
criteria are different between countries. We did not account for crossover, and in the 226 
trial 12.9% of patients in the chemotherapy arm received subsequent immunotherapy. 227 
This may potentially underestimate the survival benefit with pembrolizumab. In the 228 
sensitivity analyses we used a range for certain values to account for possible 229 
inaccuracies, as described above. Such inaccuracies may include differences between 230 
the trial participants and real world patients, as it is likely that in the real world 231 
pembrolizumab will be given to frailer patients due to its low toxicity. Also as there 232 
are no third line approved therapies, at first radiographic progression many real world 233 
patients are likely to continue therapy until the next evaluation to account for the 234 
possibility of pseudo-progression. Both differences may cause a lower utility and an 235 
increased cost of pembrolizumab, thus increasing the ICER. As vinflunine is not FDA 236 
approved and is not regularly used in clinical practice in any of the countries 237 
examined we decided not to incorporate it in the analysis. When incorporating 238 
vinflunine costs into the model the U.K. ICER changes from $91,995 to $81,850, and 239 
is still considered not to be cost-effective. To account for the possibility of no survival 240 
benefit with second-line chemotherapy we added a structural sensitivity analysis of 241 
pembrolizumab versus placebo (eTable 3 in supplement). The modeling of AEs 242 
included only significantly different incidence rates of grade 3 to 4 toxicity between 243 
treatments, thus immune-related AEs were not included due to few events. As the 244 
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recent FDA approval3 of 5 checkpoint inhibitors in second-line therapy of advanced 245 
bladder cancer changes the standard-of-care, future research would potentially include 246 
all second-line treatments with a network meta-analysis. Such an analysis would 247 
likely find pembrolizumab to be more cost-effective than the other checkpoint 248 
inhibitors, as it is the only one to currently demonstrate a survival benefit. 249 
Pembrolizumab has also recently gained approval in cisplatin-ineligible first-line 250 
advanced bladder cancer based on the Keynote 052 trial and is examined as 251 
monotherapy or in combination with chemotherapy in first-line ongoing trials. As the 252 
treatment of bladder cancer continues to rapidly evolve, there is an increasing need for 253 
the use of cost-effectiveness analyses to guide coverage decisions by payers and 254 
policy makers. This is particularly important in the United States, where drug prices 255 
are usually higher.  256 
 257 
Conclusion 258 
Costs and WTP thresholds vary between countries. Compared to the other countries 259 
examined, U.S. drug prices were found to be highest, leading to the highest ICER. 260 
Nevertheless, due to a higher WTP threshold, pembrolizumab may potentially be 261 
considered cost-effective in the U.S., but not in the other countries.    262 
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Tables and Figures 263 
Table 1 - Treatment costs 264 
Treatment cost  
($ per cycle) 
U.S., n  
(range) 
U.K., n  
(range) 
Canada, n 
(range) 
Australia, n 
(range) 
Pembrolizumab 9,691 (7,753-
11,629) 
6,816 (5,453-
8,180) 
7,053 (5,643-
8,464) 
7,563 (6,051-
9,076) 
Administration - 
Pembrolizumab 
136 (109-163) 317 (254-381) 92 (74-111) 52 (41-62) 
Chemotherapy 310 (248-372) 22 (18-26) 46 (37-55) 81 (65-97) 
Administration - 
Chemotherapy 
411 (329-493) 323 (258-387) 154 (123-185) 80 (64-96) 
Adverse Event cost 
($ per event) 
    
Anemia 1,881 (1,505-
2,258) 
756 (604-907) 464 (371-557) 781 (625-938) 
Neutropenic fever 11,565 (9,252-
13,789) 
1,632 (1,305-
1,958) 
4,244 (3,395-
5,093) 
4,523 (3,622-
5,433) 
 265 
Values in parentheses are the lower and upper bounds of the range used in sensitivity 266 
analyses. All costs are displayed in U.S. dollars, which were converted from local 267 
currencies at the exchange rates on September 1, 201723. 268 
 269 
  270 
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Table 2 - Base case results 271 
Country Incrementa
l cost 
Incremental 
effectivenes
s (QALY) 
ICER WTP 
threshol
d 
Cost-
effective
? 
U.S. $44,325 0.36 $122,557/QAL
Y 
$100,000
-
150,00017 
Yes 
U.K. $33,271 0.36 $91,995/QALY $25,000-
65,00018 
No 
Canada $33,869 0.37 $90,099/QALY $16,000-
80,00019,* 
No 
Australi
a 
$36,154 0.36 $99,966/QALY $32,000-
60,00020,* 
No 
 272 
All costs are displayed in U.S. dollars, which were converted from local currencies at 273 
the exchange rates on September 1, 201723. 274 
* For Canada and Australia there is no explicit WTP threshold for recommendation-275 
making. 276 
Abbreviations: QALY, quality adjusted life year; ICER, incremental cost-277 
effectiveness ratio; WTP, willingness-to-pay. 278 
 279 
Figure 1 – Markov model 280 
 281 
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 283 
 284 
 285 
 286 
Figure 2 - Cost-effectiveness acceptability curves in U.S. dollars 287 
 288 
 289 
  290 
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 Cost-Effectiveness of Pembrolizumab in Advanced Bladder Cancer 
Supplemental Material 
Michal Sarfaty et al. 
eTable 1: Drug costs 
Country Currency Drug Drug 
cost 
Administration 
cost 
Premedication 
cost 
Total cost 
per cycle 
Total cost 
per month 
U.S. USD Pembro 9,691 136 0 9,827 14,038.5 
U.S. USD Chemo 310.8 409 2.5 722.3 1,031.8 
U.K. GBP Pembro 5,260 245.1 0 5,505.1 7,864.4 
U.K. GBP Chemo 16.8 245.1 4 265.9 379.8 
Canada CAD Pembro 8,800 115.1 0 8,915.1 12,735.8 
Canada CAD Chemo 57.1 190.3 1.8 249.2 356 
Australia AUD Pembro 9,523.8 65 0 9,588.8 13,698.2 
Australia AUD Chemo 102.5 97.9 3.2 203.6 290.8 
  
eTable 2: Adverse event costs 
Country Currency Drug Anemia 
cost 
Incidence Total 
Anemia 
cost 
FN* cost Incidence Total 
FN* 
cost 
Total 
AE 
cost 
U.S. USD Pembr
o 
1,881.3 0.8% 15 11,565.6 0.0% 0 15 
U.S. USD Chemo 1,881.3 7.8% 146.7 11,565.6 7.0% 821.1 967.8 
U.K. GBP Pembr
o 
583 0.8% 4.6 1,259 0.0% 0 4.6 
U.K. GBP Chemo 583 7.8% 45.4 1,259 7.0% 88.1 133.5 
Canada CAD Pembr
o 
579 0.8% 4.6 5,295.7 0.0% 0 4.6 
Canada CAD Chemo 579 7.8% 45.1 5,295.7 7.0% 370.6 415.7 
Australia AUD Pembr
o 
984.1 0.8% 7.8 5,701.3 0.0% 0 7.8 
Australia AUD Chemo 984.1 7.8% 76.7 5,701.3 7.0% 399 475.7 
*FN = febrile neutropenia 
 
eTable 3: Structural sensitivity analysis – Pembrolizumab versus Placebo 
Country Incremental 
cost 
Incremental 
effectiveness (QALY) 
ICER WTP threshold Cost-
effective? 
U.S. $48,137 0.36 $133,083/QALY $100,000-
150,00016 
Yes 
U.K. $35,026 0.36 $96,834/QALY $25,000-65,00017 No 
Canada $35,222 0.37 $97,377/QALY $16,000-80,00018,* No 
Australia $37,579 0.36 $103,894/QALY $32,000-60,00019,* No 
All costs are displayed in U.S. dollars, which were converted from local currencies at the exchange rates on 
September 1, 201722. 
* For Canada and Australia there is no explicit WTP threshold for recommendation-making. 
  
Costs 
We adjusted all cost estimates for each individual country. All costs were sourced between 2013 and 2017 
and were converted from local currency to U.S. dollars using the exchange rates on September 1, 2017: one 
U.S. dollar was equivalent to 0.77 U.K. pounds, 1.25 Australian dollars and 1.24 Canadian dollars1. We did 
not include sales tax.  
U.S. Costs 
For US prices we used the 2016 average sales price by the Centers for Medicare and Medicaid services plus 
4.2% to simulate Medicare reimbursement. Administration costs and adverse event costs were calculated 
according to the Medicare physician fee schedule for 2016. The costs for grade 3/4 AEs were based on 
diagnosis related group (DRG) codes. The fees for outpatient physician visits were based on Current 
Procedure Terminology codes2,3. 
U.K. Costs 
To estimate the unit price for generic drugs, we used the U.K. Department of Health Commercial Medicines 
Unit electronic Medicines Information Tool4. To estimate the unit price for patented drugs, we used the U.K. 
list price as published in the British National Formulary5. This represents the national Drug Tariff arising 
from negotiation on a 5-year cycle as part of the Pharmaceuticals Pricing and Reimbursement Scheme. Costs 
for chemotherapy administration and outpatient physician visits were taken from the National Health 
Service (NHS) Reference costs, which are published annually on the basis of average costs returned by 
individual NHS healthcare providers6. 
Canada Costs 
To estimate the unit price of drugs, we used the Ontario Drug Benefit Formulary7 and Sunnybrook 
Pharmacy Stores Department (Kelvin Chan, personal communication). The costs of chemotherapy 
supervision were estimated by duration of nursing and pharmacy time as estimated by Cancer Care Ontario8 
and multiplied by their estimated hourly wage9. The outpatient physician visits cost was obtained from the 
Ontario Schedule of Benefits10. In Ontario, Canada, there is a differential pricing structure for clinic visits 
based on the number of prior visits. In order to make appropriate comparisons between countries and not to 
adjust the overall design of the model, we estimated the price of a single clinic visit as the mean of the first 
five clinic visits. Although any difference in actual prices would likely have only a tiny impact on the model 
results, these differences would be accounted for in the subsequent sensitivity analyses. 
Australia Costs 
Drug prices were collected from the 2017 Pharmaceutical Benefits Scheme prices11. This is a federally 
funded pharmaceutical scheme with nationwide coverage. Administration costs and physician visits were 
based on the 2017 Medicare Benefits Schedule prices for outpatient health services12. Blood products were 
based on the 2017 National Blood Authority Australia prices13.  
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eFigure 1: Overall Survival Curve- Pembrolizumab versus Chemotherapy 
 
 
eFigure 2: Progression-free Survival Curve- Pembrolizumab versus Chemotherapy 
 
